Clinical Trials Browser

Panitumumab × Gastrointestinal × 90 days × Clear all

NCT07543744 2026-04-22

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

Phase 1 Recruiting

180 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 1/2 Recruiting

554 enrolled

CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT06820463 2026-04-15

AndroMETa-CRC

Phase 2 Recruiting

390 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07094204 2026-04-15

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Phase 1 Recruiting

364 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT02394834 2026-04-13

An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Active not recruiting

757 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06252649 2026-04-02

CodeBreaK 301

Phase 3 Recruiting

450 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06998940 2026-03-27

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Phase 3 Recruiting

94 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05863195 2026-03-23

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3 Recruiting

408 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03384238 2026-03-17

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Phase 1/2 Recruiting

27 enrolled

Gastrointestinal

Pancreatic Adenocarcinoma

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2 Recruiting

197 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Active not recruiting

2 enrolled

Gastrointestinal

Colonic Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Not yet recruiting

100 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07094113 2026-02-12

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

434 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03693807 2026-02-06

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Phase 2 Completed

35 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms, Cholangiocarcinoma

NCT05198934 2026-02-06

CodeBreak300

Phase 3 Active not recruiting

160 enrolled 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Phase 2 Active not recruiting

34 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06268015 2026-02-05

BBOpCo

Phase 2 Active not recruiting

16 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT04787341 2026-02-02

PARERE

Phase 2 Active not recruiting

214 enrolled

Gastrointestinal

Colorectal Neoplasms